Ronald Seidel, Ph.D.

Ron Seidel is co-founder and CEO of Crosslink Therapeutics and co-inventor of its technologies. Prior to Crosslink, Dr. Seidel was a co-founder/co-inventor of Cue Biopharma (NASDAQ: CUE).  At Cue, Dr. Seidel served as EVP and head of R&D with oversight of daily company operations integrating R&D and intellectual property development strategy with operational capabilities and scientific direction. Prior to Cue, Dr. Seidel was a Research Assistant Professor of Biochemistry and Associate Director of the Macromolecular Therapeutic Development Facility (MTDF) at the Albert Einstein College of Medicine. Dr. Seidel holds a B.S. and Ph.D. in Biochemistry/Structural Biology from the University of Georgia.